Radiopharm enters co-development partnership with Lantheus

Radiopharm Theranostics (RADX) has entered into a strategic co-development partnership with Lantheus (LNTH) to advance the clinical development of innovative radiopharmaceuticals in Australia. Under the agreement, Radiopharm will lead clinical development efforts in Australia, leveraging its extensive experience and infrastructure to drive advancements in the field. The collaboration includes plans for a basket clinical trial targeting multiple solid tumors, underscoring both companies’ commitment to addressing unmet medical needs in oncology. As part of the partnership, Lantheus will cover all clinical development costs associated with the program. Additionally, Radiopharm will receive up to $2M as milestone payments upon achieving key clinical development objectives, including ethics committee approval, first patient dosing, and completion of patient enrolment, for the first imaging trial subject to this agreement.